ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Sanofi moves up opening of Singapore vaccine plant to 2025

Drugmaker ushers in 'the future' with modular production and AI

The Singapore plant will produce vaccines, including those using mRNA technology, mainly for the Asian market. (Photo courtesy of Sanofi)

SINGAPORE -- French drugmaker Sanofi plans to bring its new vaccine plant in Singapore fully online by the end of 2025 as it looks to tap growing demand for preventive care in an aging Asia.

A groundbreaking ceremony was held Wednesday for the 400 million euro ($434 million) production facility. It was initially slated to start fully operating in the first quarter of 2026, but the company moved up the timeline to match changes to production and sales plans.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more